1. Home
  2. BAFN vs ALXO Comparison

BAFN vs ALXO Comparison

Compare BAFN & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

HOLD

Current Price

$8.00

Market Cap

40.6M

Sector

Finance

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.51

Market Cap

79.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAFN
ALXO
Founded
1999
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.6M
79.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BAFN
ALXO
Price
$8.00
$1.51
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$3.30
AVG Volume (30 Days)
5.2K
267.7K
Earning Date
01-29-2026
11-07-2025
Dividend Yield
2.00%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$58,931,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.40
$0.40
52 Week High
$19.75
$2.27

Technical Indicators

Market Signals
Indicator
BAFN
ALXO
Relative Strength Index (RSI) 44.07 54.56
Support Level $7.90 $1.29
Resistance Level $8.07 $1.57
Average True Range (ATR) 0.11 0.12
MACD 0.06 0.02
Stochastic Oscillator 32.20 80.00

Price Performance

Historical Comparison
BAFN
ALXO

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: